Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone.
Dühmke E, Diehl V, Loeffler M, Mueller RP, Ruehl U, Willich N, Georgii A, Roth S, Matthaei D, Sehlen S, Brosteanu O, Hasenclever D, Wilkowski R, Becker K. Dühmke E, et al. Among authors: brosteanu o. Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):305-10. doi: 10.1016/s0360-3016(96)00333-1. Int J Radiat Oncol Biol Phys. 1996. PMID: 8892452 Clinical Trial.
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.
Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Crowther D, Diehl V, Fisher RI, Hoppe RT, Jacobs P, Pater JL, Pavlovsky S, Thompson E, Wiernik P. Loeffler M, et al. Among authors: brosteanu o. J Clin Oncol. 1998 Mar;16(3):818-29. doi: 10.1200/JCO.1998.16.3.818. J Clin Oncol. 1998. PMID: 9508162
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
Dühmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Rühl U, Müller RP, Lukas P, Atzinger A, Paulus U, Lathan B, Rüffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, Fritsch E, Koch P, Drochtert A, Brosteanu O, Hasenclever D, Loeffler M, Diehl V. Dühmke E, et al. Among authors: brosteanu o. J Clin Oncol. 2001 Jun 1;19(11):2905-14. doi: 10.1200/JCO.2001.19.11.2905. J Clin Oncol. 2001. PMID: 11387364 Clinical Trial.
Modelling of chemotherapy: the effective dose approach.
Hasenclever D, Brosteanu O, Gerike T, Loeffler M. Hasenclever D, et al. Among authors: brosteanu o. Ann Hematol. 2001;80 Suppl 3:B89-94. doi: 10.1007/pl00022800. Ann Hematol. 2001. PMID: 11757718 Review.
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Sieber M, et al. Among authors: brosteanu o. J Clin Oncol. 2002 Jan 15;20(2):476-84. doi: 10.1200/JCO.2002.20.2.476. J Clin Oncol. 2002. PMID: 11786577 Clinical Trial.
Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity?
Carde P, Koscielny S, Franklin J, Axdorph U, Raemaekers J, Diehl V, Aleman B, Brosteanu O, Hasenclever D, Oberlin O, Bonvin N, Björkholm M. Carde P, et al. Among authors: brosteanu o. Ann Oncol. 2002;13 Suppl 1:86-91. doi: 10.1093/annonc/13.s1.86. Ann Oncol. 2002. PMID: 12078910 Free article. Review.
45 results